In the BioHarmony Drug Report Database
Crizanlizumab-tmca
Adakveo (crizanlizumab) is an antibody pharmaceutical. Crizanlizumab was first approved as Adakveo on 2019-11-15. It has been approved in Europe to treat sickle cell anemia. It is known to target P-selectin.
Trade Name
|
Adakveo |
|---|---|
Common Name
|
crizanlizumab |
ChEMBL ID
|
CHEMBL4297734 |
Indication
|
sickle cell anemia |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
